M4DM4X wrote: I've been investing and trading MJ since 2015, I'm well aware of US legislation, the SAFE act, etc.
Presently, the EU for the most part is a medical/CBD play; chemical quality matters, smoking quality not so much. Chemical quality can be altered/concentrated, even garbage outdoor Indian bud can make potent CBD oil.
However, FIRE is
branding themselves as the best rec. play in the business, so you can draw your own conclusions, but the market (and myself) doesn't think EU is a good play for FIRE in 2019.
The fact is the companies that will still exist in 5 years are the ones that are setting themselves up
now for US rec -
This is the only rec. market that matters. Don't kid yourself, the Canadian/EU rec. market is a joke compared to the US.
Here are examples of CAD Co's that show a direct path into the USA given the current legislation:
HEXO - Set up a US branch, and partnered with Coors - They show a direct path into the USA
CRON - Deal with Altria, direct path to US through Altria
CGC/WEED and their tentative buyout of ACRG (US based). Not sure what you mean by "where it has taken them", contract has a 7.5 year timeframe.
And to a lesser degree FAF - Deal with Couche-Tard, which has stores around the world, possible entry opp for FAF.
Do yourself a favor MD, take a look at current US operators, like Medmen, or GTII, or Curaleaf, Trulieve, look at how they're working within the laws while setting themselves up for legalization.
TRUL booked $319M annual sales, and a
positive EPS of $1.05, and this is now in 2019 while MJ still isn't federally legal.
Supreme isn't big enough to set up a true US branch, so they need a deal, potential partnership, JV, etc. with a
US MSO or a US Co - and they need it
now not in 2 years.
Lastly, if Supreme had deals,
they are legally obligated to announce them, just like the other big boys up in the TSX - So NO they currently don't have anything, but hopefully they'll announce something on Wednesday, or before 2020.
maritimedreamer wrote: The push into the US will be important.... but that will only be when the road to legalization in the US has become more clear, and you know maybe not be classed as a Schedule 1 drug. Why take such risks with capital employment when anything can happen as nothing is set in stone. Look at Canopy's purchase.... and where that has taken them...... The US will certainly be integral for growth at some point but right now i believe the risk far outweighs the benefits...... The EU is where Supreme should be focusing for the now.........
Laslty, would you not think Supreme is already all over that just not made public yet? ..... they probably know their steps to take once things are formally in place.